
A phase 3 trial, ICON8, compared standard-of-care chemotherapy with dose-dense chemotherapy in women with newly diagnosed epithelial ovarian cancer. The dose-dense regimen included weekly paclitaxel and 3-weekly carboplatin. The trial enrolled 1566 patients and followed them for about 69 months. The results showed no significant improvement in overall survival or progression-free survival with the dose-dense regimen compared to the standard 3-weekly chemotherapy. The most common grade 3–4 adverse events were reduced neutrophil count, reduced white blood cell count, and anemia. Based on these findings, first-line weekly dose-dense chemotherapy should not be used as part of standard multimodality front-line therapy for this type of ovarian cancer.
Like
Save
Share